// App-Quantinova.ai

: Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.

Researchers

Presenter

  • Mohamed Bouattour

Principal Investigators

  • Juan W. Valle

  • Arndt Vogel

  • Jin Won Kim

  • Masayuki Kitano

  • Jen-Shi Chen

  • Howard A. Burris III

  • Renata Zaucha

  • Shukui Qin

  • Ludovic Evesque

  • David Bing Zhen

  • Vineet Govinda Gupta

  • Joon Oh Park

  • Magdalena Żotkiewicz

  • Nana Rokutanda

  • Gordon Cohen

  • Do-Youn Oh

Medical Centers

  • Jinling Hospital, Nanjing University School of Medicine, Nanjing, China

  • Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Department of Hematology-Oncology, Linkou Chang-Gung Memorial Hospital and Chang-Gung University, Tao-Yuan City, Taiwan

  • Dept. of Oncology and Radiotherapy, Medical University of Gdansk, Gdanks, Poland.

  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of (South), Korea

  • Centre Antoine Lacassagne, Department dOncologie Medicale, Nice, France

  • Division of Hematology-Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

  • Artemis Hospital, Gurgoan, India

  • Oncology Biometrics, Late Oncology Statistics, AstraZeneca, Warsaw, Poland

  • Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg, MD

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

  • Clinic of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

  • Division of Medical Oncology, Department of Medicine, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA

  • Department of Liver Cancer Unit, Assistance Publique–Hôpitaux de Paris Hôpital Beaujon, Paris, France

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Locations

  • United Kingdom

  • Republic of South Korea

  • Poland

  • United States

  • India

  • China

  • Taiwan

  • Germany

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Durvalumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT03875235

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved